Published in Cancer Weekly, May 14th, 2002
SI-27 has been tested on human endothelial cells at Tokyo, Japan's Nippon Medical School. Those test results show SI-27 prevents angiogenesis by blocking matrix metalloproteinases (MMPs), or enzymes that degrade extracellular proteins. Because of this specificity, SI-27 holds the potential for being a useful therapy for selected diseases caused by pathologic angiogenesis.
Daizo Yoshida and associates in the Department of Neurosurgery coauthored the study with colleagues in the Central Institute for Electron...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.